CluenexBio-Techne TECH
Bio-Techne scores average on business quality (5.8 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What Bio-Techne does
Bio-Techne sells life science reagents, instruments, and clinical diagnostics to research labs and healthcare providers, generating $1.2 billion in revenue. Leadership is navigating flat top-line performance while managing insider transactions like John L Higgins executing options worth $751K.
- What it does best
Bio-Techne secures elite pricing power through specialized reagents, posting a gross margin of 66.3% that comfortably outpaces peers like Charles River Laboratories at 34.6%. This high margin stems from deeply embedded laboratory protocols that make switching suppliers risky for researchers.
- The main risk
Stagnant top-line growth presents a primary risk, with revenue contracting 0.4% year-over-year as demand flattens. Without an expanding revenue base, earnings rely entirely on cost control rather than market expansion.
Quality, check by check
Scored against its own industry, from company filings.
Operating margins hold strong at 23.5% alongside a free cash flow margin in the top quartile of the sector at 71st percentile. Cash conversion remains exceptionally high, though overall profitability scales moderately while top-line growth stays flat.
Switching costs anchor the moat, locking in research laboratories that rely on consistent biological reagents for reproducible experiments. Its gross margin ranks in the top half of the sector at 54th percentile, protecting pricing power against cheaper alternatives.
Revenue growth is currently stalled at negative 0.4%, down from historical levels as core markets mature. The top-line trend shows a flat profile over the past two annual cycles, moving sideways rather than advancing.
Debt-to-equity sits at a modest 0.1, backed by $265 million in cash and interest coverage of nearly 30x. Free cash flow reached $263 million, marking a steady upward drift over the last three years and keeping the balance sheet firmly secure.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
No open market buys or unplanned sales by executives or directors.
Our sealed record on TECH
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
Bio-Techne scores average on the Cluenex quality check (5.8 of 10), measured against its own industry. Profitability is fair, moat fair, growth slow and financial health strong.
In the last 90 days of SEC Form 4 filings: No open market buys or unplanned sales by executives or directors.
Nov 3, 2026.
See TECH today
- Today's verdict on TECH, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “Bio-Techne (TECH)”, https://cluenex.com/stocks/tech/, data as of Oct 10, 2026.